Russia’s competition authority approved of Sistema’s buyout of Veropharm on Monday, and, as a result, shares surged in the Moscow stock exchange for two of nation’s pharmaceutical companies, Veropharm and 36.6. Shares in 36.6 rose 6.7 percent, while shares for Veroharm – Russia’s third largest drug maker – rose 9.7 percent. 36.6 had previously announced it was ready to sell its share in Veropharm, which amounted to 51.8 percent of the company, to pay off debts. Russia’s Federal Anti-Monopoly Service has approved of the merger as long as certain conditions are met, though there is no word yet on what those conditions are.
Featured News
US Appeals Court Tosses FTC Order Over Intuit’s “Free” TurboTax Ads
Mar 22, 2026 by
CPI
Jury Finds Musk Liable for Misleading Twitter Shareholders During Takeover Fight
Mar 22, 2026 by
CPI
FTC Launches Healthcare Task Force to Sharpen Enforcement
Mar 22, 2026 by
CPI
White House Pushes Congress for National AI Law to Override State Rules
Mar 22, 2026 by
CPI
Anthropic Copyright Settlement Lawyers Cut Fee Request to $187.5 Million
Mar 22, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data-Driven Competition
Mar 19, 2026 by
CPI
Data-Driven Competition: Implications For Enforcement and Merger Control
Mar 19, 2026 by
Alexandre de Corniere & Greg Taylor
From Tipping to Trustees: Why Data-Driven Markets Require Institutional Design, Not Optimization
Mar 19, 2026 by
Jens Prüfer & Paul de Bijl
Data Barriers to Entry: What We’ve Learned About Spotting Them and What We Still Don’t Know About Solutions
Mar 19, 2026 by
Bruno Carballa-Smichowski
When the Perfect Is the Enemy of the Good: Price Discrimination, Affordability, Precarity and Market Dynamism
Mar 19, 2026 by
Dan Ciuriak